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The Effects of Perfluorooctylbromide Emulsions on Myocardial 
Function, ATP Levels and The Antioxidant Defense System in 
An In Vitro Rat Model of Cardioplegia-induced 
Ischemia/Reperfusion Injury (70 pp.)
Director; Charles L. Eyer, Ph.D. j _
Protective effects of perfluorooctylbromide emulsions 
on myocardial ischemia and reperfusion (MI/R) injury were 
evaluated in a modified Langendorff rat heart preparation. 
Isolated rat hearts were equilibrated in Krebs-Henseleit 
solution (KH) for 35 minutes and perfused with cardioplegic 
solution (CPS) for 3 minutes. Control hearts were bathed in 
the CPS. Treated hearts were given a single infusion of 
100%, 50% or 25% PFOB emulsified in CPS and then bathed in 
the emulsions. All treatment groups were subjected to 3 5 
minutes of ischemia. Following reperfusion with KH 
solution, hearts subjected to 100% or 50% PFOB emulsions 
showed improved recovery of left ventricular function. The 
2 5% PFOB emulsion did not differ from the control. Tissue 
activities of the antioxidant enzymes glutathione 
peroxidase, superoxide dismutase, and catalase were not 
changed by MI/R injury in this model. A 100% PFOB emulsion 
produced no effect on these enzymes. Levels of ATP and 
reduced and oxidized glutathione (GSH and GSSG respectively) 
were also determined in preischemic hearts and after 
ischemia and reperfusion in both control and 100% PFOB 
treated hearts. No differences were noted in GSSG levels. 
However, cardioplegia-induced MI/R injury decreased 
myocardial ATP and GSH levels. The 100% PFOB emulsion 
prevented the decline in these substances.
These data suggest that PFOB emulsions protect the 
myocardium against injury associated with cardioplegia and 
reperfusion.
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INTRODUCTION
1. Myocardial Ischemia and Reperfusion Injury
The heart is dependent on aerobic metabolism for energy 
production. Ischemia occurs when coronary flow is 
insufficient to supply the necessary oxygen for oxidatiye 
phosphorylation and to remoye cellular metabolites (Jennings 
1970). Restoration of the coronary arterial flow after a 
yariable period of ischemia is called reperfusion.
Myocardial ischemia and reperfusion (MI/R) injury is 
produced during ischemia and exacerbated during the 
reperfusion period (Jennings et al 1985, Gettes et al 1991 
and Rao et al 1983) .
Three leyels of MI/R injury are currently recognized 
(Downey 1990). The first leyel of injury produces 
arrhythmias generated upon reperfusion after an ischemic 
period of a few minutes (Bernier et al 1986). The second 
leyel deyelops after 5 to 15 minutes of ischemia followed by 
reperfusion and is characterized by a prolonged decrease in 
contractility. This state is also referred to as myocardial 
stunning. Generally, the heart will completely recoyer 
after seyeral days (Bolli 1988, Farber et al 1988, Przyklenk 
et al 1986). The most seyere type occurs when the ischemic 
period is extended to 20 minute or longer. Some of the heart 
cells will be irreyersibly injured and necrotic (Groyer et 
al. 1990, Maxwell et al 1989). The third leyel of injury.
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infarction, has attracted the greatest attention because 
infarcted tissue contributes to mortality and morbidity in 
the clinic. A lot of research about MI/R has been devoted 
to establishing the mechanisms involved in the development 
of irreversible tissue injury. Protective effects of 
different kinds of substances have been evaluated mainly in 
models of irreversible MI/R injury (Maxwell et al 1989, 
Grover et al 1990, Teoh et al 1990).
A number of different experimental models have been 
employed in such evaluations. These include: (a) regional
or global ischemia following coronary artery occlusion or 
clamping the aorta in vivo (Maxwell et al 1989, Godin et al 
1980, Teoh et al 1990), (b) total or low flow ischemia in
isolated perfused hearts or septa (Ferrari et al 1985,
Grover et al 1990, Downey et al 1987), (c) cardioplegia in
experimental animals (Teoh et al 1990, Jones et al 1982). 
Experiments have also been done in other models such as a 
cardiac myocyte preparation (Goldhaber et al 1989, Cheung et 
ai 1984) .
2. Mechanisms of MI/R iniurv
Contractile function of myocardium depends on the 
hydrolysis of high energy phosphates. The absence of 
sufficient arterial flow causes a rapid lowering of 
myocardial PO 2 and a loss of aerobic metabolism (Gettes 
198 6 ). The maximum rate of ATP production from anaerobic
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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glycolysis is less than 1 0 % of the rate of oxidative 
phosphorylation necessary to sustain cardiac function 
(Kobayashi et al 1979). Insufficient substrate delivery 
leads to rapid depletion of high energy phosphates. 
Myocardial contraction will stop in less than one minute 
after global ischemia (Reimer et al 1986).
Excessive intracellular Ca^^ has been implicated as a 
primary event in irreversible MI/R injury and cell necrosis 
(Farber 19 82). The mechanisms involved in the accumulation 
are very complex. Depletion of ATP causes increased 
intracellular Na+. The rise of intracellular Na"̂  is thought 
to increase intracellular Ca2+ via the Na/Ca exchange 
mechanism (Reuter and Scholz 1968) . The increased Câ "*" 
release and decreased re-uptake by the sarcoplasmic 
reticulum is also thought to elevate the Ca^^ inside the 
cell (Gettes et al 1991). The third mechanism results from 
the reduced activity of sarcolemmal Ca^^ ATPase which leads 
to a reduction of Ca^^ efflux and net Ca2+ uptake. During 
reperfusion, the enhanced influx of Câ '*’ through Câ '*' 
channels may also contribute to the large increase of 
intracellular Ca^^ (Tani and Neely 1988). In addition, 
oxygen free radicals produced primarily upon reperfusion may 
be involved in Ca^+ overloading. Lipid peroxidation of 
cellular structures by these free radicals can exacerbate 
the above mentioned ionic perturbations (Hearse et al 1988). 
The raised cytosolic Câ '*' in the prolonged ischemic and
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reperfused myocardium results in an irreversible increase in 
resting tension (contracture) forming rigor complexes (Lowe 
et al 1979). Shortening of the myofibril associated with 
contracture-rigor may be due to the loss of structural 
integrity in lethally injured myocytes (Ganote 1983). 
Moreover, the contracture-rigor may compress blood vessels 
and thus restrict reperfusion capacity (Gavin et al 1978).
The lack of venous washout secondary to the diminution 
of arterial flow causes several extracellular ionic and 
metabolic changes, such as decreased pH and accumulation of 
lactate, catecholamines and lysophosphatides (Gettes et al 
1991). Some of the alterations have been postulated to 
disrupt membrane protein function and to change cellular 
electrophysiology (Corrie and Dobmeyer 1989).
Myocardial edema is another consequence of this 
myocardial deterioration (Goto et al 1991). Edema results 
from the increased intracellular concentrations of osmotic 
particles such as H 2 PO 4 ", lactate and produced during 
ischemia. Enhanced tissue osmolality leads to cellular 
swelling and eventually to membrane disruption.
Oxygen-derived free radicals generated during 
myocardial ischemia and reperfusion are also responsible for 
MI/R injury. These radicals are capable of various toxic 
activities such as inactivation of sulfhydryl enzymes, 
crosslinking of proteins, DNA breakdown, and lipid 
peroxidation which causes membrane disruption (Freeman and
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
Crapo 1982, Bielski et al 1983, Brown et al 1988, Baker et 
al 1988). In addition, free radicals may cause contractile 
dysfunction by inhibition of glycolysis and oxidative 
phosphorylation (Goldhaber et al 1989).
Free radicals are compounds that have unpaired 
electrons in their outer shell. This unpaired state makes 
them very unstable and prone to react with other molecules 
to either gain or lose electrons (Downey 1990). Oxygen- 
derived free radicals include the superoxide anion, hydroxyl 
radical and hydroperoxyl radical. Hydrogen peroxide, which 
although technically not a radical, is generally included in 
this list because it is the most common precursor of the 
hydroxyl radical. The hydroxyl radical is proposed to be 
the most reactive of these compounds. It has a short half- 
life and usually will react within 1 to 5 molecular 
diameters of its site of formation (Pryor 1986). The 
primary reactant that serves as the ultimate source for each 
of the oxidants is superoxide. Superoxide can be easily 
changed to hydrogen peroxide by superoxide dismutase (SOD), 
The hydroperoxyl radical is formed in the biological system 
by protonation of superoxide (Bielski et al 1983).
Several possible sources of oxyradicals exist:
(A), Xanthine oxidase. Hypoxanthine release from the 
ischemic heart as a consequence of increased ATP degradation 
is oxidized by xanthine oxidase, generating superoxide and 
hydrogen peroxide. An additional important feature of this
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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hypothesis is the conversion of xanthine dehydrogenase to 
xanthine oxidase through proteolysis caused by ischemia 
(Brown et al 1988, McCord 1985, Chambers et al 1985). The 
enzyme is thought to exist primarily as a dehydrogenase form 
in normal myocardium and does not generate free radicals.
While ischemic rat and dog hearts have abundant 
xanthine oxidase, the rabbit and human hearts contain minute 
amounts of the enzyme (Downey et al 1987, Godin and Bhimji 
1987, Muxfeldt and Schaper 1987). This limits the 
usefulness of xanthine oxidase inhibitors, such as 
allopurinol, in MI/R injury.
(B). Dissociation of the intramitochondrial electron 
transport chain, also called mitochondrial "leak" (Turrens 
and Boveris 1980, Shlafer et al 1987). This is caused by 
altered phospholipid integrity which inactivates cytochrome 
oxidase, resulting in release of superoxide radicals.
(C). Auto-oxidation of various substances (Werns et al 
1985, Rao et al 1983, Fridovich 1983, Jewett et al 1989), 
such as catecholamines, flavoproteins, NADH, hemoglobin, 
myoglobin, and reduced cytochrome c.
(D). Activation of Phospholipase A 2 by calcium influx. 
This initiates production of a fatty acid, arachidonic acid 
(AA), from cell membrane phospholipids. Major metabolites 
of AA include prostaglandins. Biosynthesis of 
prostaglandins from AA can generate radicals (Kontos et al 
1985, Mathews and Holde 1990).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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(E). Leukocyte mediated free radical generation 
(Lucchesi 1986 and 1990). Leukocytes were found in 
infarcted myocardium several decades ago (Mallory et al 
1939, Fishbern et al 1978). Recent studies have shown that 
leukocytes are activated and accumulate in ischemic and 
nonischemic areas (Mullane et al 1984 Pinckard et al 1980). 
After the onset of ischemia, the initial damage of the 
myocardium activates the complement system, which in turn, 
promotes neutrophil activation and infiltration (McManus et 
al 1983). Once activated, leukocytes can release a variety 
of mediators that are bacteriocidal and potentially toxic to 
tissue. Among these mediators are the free radicals.
Another important neutrophilic enzyme is myeloperoxidase.
Its reaction with H 2 O 2 can oxidize various halides, like Cl” 
, to produce toxic products such as HOCl (Harrison and 
Schulz 1976). Other mediators released from leukocytes 
include platelet-activating factor (Lepran and Lefter 1985), 
arachidonic acid, arachidonic acid metabolites and lysosomal 
enzymes.
(F). Ferrous and ferric ion. Iron ions catalyze the 
Fenton reaction that converts hydrogen peroxide to hydroxyl 
radical; in phosphate buffered media at neutral pH these 
ferric and ferrous ions undergo cyclic oxidation-reduction 
reactions which are coupled with conversion of oxygen into 
superoxide (Cohen and Sinet 1980). Contaminant iron in the 
buffer can account for this radical generation in
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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experimental models in vitro. In vivo the free iron in the 
blood can also undergo this auto-oxidation. Furthermore, 
free iron may be released by superoxide from iron-binding 
proteins during MI/R (Thomas et al 1985).
Although the above mentioned mechanisms involved in 
free radical generation begin during ischemia, the greatest 
generation of free radicals occurs during reperfusion (Werns 
et al 1985, Downey 1990).
An additional mechanism that may contributes to MI/R 
injury is the decreased defense against free radicals in 
cells following ischemic damage (Godin et aI 1989, Ferrari 
et al 1985, Julicher et al 1984). Free radicals are 
produced by normal physiological processes. The biosystem 
has natural defense mechanisms to protect cells. Endogenous 
antioxidant molecules such as glutathione (GSH), vitamin E, 
ascorbic acid, and cysteine prevent oxidative damage 
(Cotgreave et al 1988). This defense also includes the 
enzymes superoxide dismutase (SOD), catalase (CAT), 
glutathione peroxidase (GPD), cytochrome C peroxidase, 
ascorbate peroxidase, and GSH transferases. SOD catalyzes a 
dismutation in which two superoxides are transformed into 
one H 2 O 2 and one O 2 . CAT converts H 2 O 2 to O 2 and H 2 O while 
the GPD reduces H 2 O 2 to H 2 O coincident with the oxidation of 
glutathione (GSH) to glutathione disulfide (GSSG) (Mathews 
and Holde 1990 pp. 534-535).
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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Mechanisms that contribute to MI/R injury do not work 
independently. Many interrelationships exist between them 
and generally they enhance each other.
Along with the discoveries about the mechanisms 
involved in the MI/R injury, a variety of therapeutic 
interventions have been developed. Antioxidant enzymes such 
as SOD and CAT and free radical scavengers such as a- 
tocopherol were demonstrated to reduce the damage in 
different experimental models (Guarnieri et al 1978, Bolli 
et al 1989, Shlafer et al 1982). Exposure to endotoxin and 
hyperthermic stress can induce synthesis of endogenous 
tissue antioxidants and can attenuate the injury (Bensard et 
al 1990, Currie et al 1988). Calcium antagonists have 
protective effects against MI/R damage by reducing the Ca^"^ 
overloading (Ferrari et al 1991). Werns et al (1988) found 
that inactivators of neutrophils have the ability to reduce 
myocardial necrosis. The iron chelator desferrioxamine 
limits MI/R in some experimental models (Liu et al 1990). 
Enhanced oxygen delivery by perfluorocarbons during ischemia 
and cardioplegia is protective in MI/R injury models (Tomera 
et al 1982).
3. Cardioplegia
In order to expedite cardiac surgery and 
transplantation, the heart is arrested with cardioplegic 
solutions (CPS) which normally contain high potassium
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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concentrations to stop the heart in diastole. The heart is 
ischemic during the cardioplegic period and variable MI/R 
injury occurs (Hearse et al 1981, pp.5-6).
The earliest open-heart surgery primarily employed 
moderate or profound hypothermia to reduce cardiac damage 
(Bigelow et al 1950,1954; Drew and Anderson 1959). The 
severe time limitation and difficulty in maintaining 
hypothermia led to the development of other methods of 
myocardial protection. In addition, some surgeons used 
cardiopulmonary bypass with a pump oxygenator, keeping the 
coronary arteries perfused and the heart beating which 
obviously intensified the difficulties of the surgery (Isom 
et al 1973).
Melrose and colleagues (1955) introduced the concept of 
"elective cardiac arrest" or cardioplegia. After occluding 
the aorta, they rapidly injected a 2.5% solution of 
potassium citrate in whole blood into the aortic root to 
arrest the heart. However, the Melrose technique was later 
abandoned because of myocardial injury associated with 
potassium citrate (McFarland et al i960). Subsequently, 
methods such as coronary perfusion, intermittent aortic 
occlusion, topical hypothermia and ischemia at normal 
temperature were employed by different groups around the 
world (Hearse et al 1981, pp.7-12).
The need to protect the myocardium and at the same time 
to maintain a clear operating field for surgery preserved
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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interest in cardioplegia. This led to a better 
understanding of the factors which are necessary to safely 
induce chemical arrest while preserving cell structure and 
function. Actually the reported effects of potassium 
citrate may have been due to tissue ischemia. Gay and Ebert 
(1973), Holscher (1967) and Tyers et al (1975) suggested 
that the high concentrations of potassium and citrate were 
responsible for much of the damage. CPS of the 1960's and 
1970's contained components which differed from the initial 
formula (2.5% potassium citrate) and also differed from each 
other. Hearse (1974, 1975 and 1976) tested experimentally 
the individual components of these solutions on the isolated 
rat heart in the Rayne Institute at St Thomas* Hospital in 
London. He advocated that CPS should retain as closely as 
possible extracellular, rather than intracellular, 
concentrations of ions. He also recommended that additions 
which were individually effective would be used only in 
their optimal concentrations. The "St Thomas Solution" he 
proposed based on this principle contained physiological 
concentrations of sodium and calcium to which were added 16 
mmoles/L KCl to arrest the heart instantly, 16mmoles/L MgCl 
which had been shown to have a marked additive effect to the 
potassium for myocardial protection, and 1 mmole/L procaine 
hydrochloride. This is the formula of the St. Thomas' 
Hospital Cardioplegia Solution No.1 which was used 
continuously between 1975 and 1981 (Hearse et al 1981,
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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pp.12-14). Worldwide clinical experiences with this or 
other very similar solutions indicated that they induced 
cardiac arrest rapidly and, in combination with topical 
hypothermia, afforded excellent myocardial preservation 
(Braimbridge et al 1977, Conti et al 1978, Cooley 1979,
Tyers et al 1977). In 1981, this formulation was modified 
to include buffering and pH control with a small reduction 
in sodium and calcium (Hearse et al 1981, pp.159). This 
modified solution is now called St. Thomas* Hospital 
Cardioplegia Solution No.2 and is the most widely used CPS 
in the United States and Europe (Ledingham et al 1990).
The overall protection afforded by cold chemical 
cardioplegia is contributed by three important components: 
energy conservation through the rapid chemical induction of 
cardiac arrest, the slowing of metabolism and degenerative 
processes by hypothermia, and the prevention of unfavorable 
cellular changes by the inclusion of specific protective 
agents in the cardioplegic solution (Hearse et al 1981, 
pp.151).
Chemical induction of cardiac arrest is most commonly 
produced by mild hyperkalemia (Melrose et al 1955). Within 
its optimal concentration range (between 10 and 3 0 meq/L), 
potassium very effectively arrests the heart in diastole 
with few side effects on tissue (Tyers et al 1977, Buckberg 
1979). Substantial depletion of calcium and sodium can also 
induce cardiac arrest (Gebhard et al 1983). However, they
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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also produce harmful effects on the cells (Gordon et al 
1978, Sachror et al 1979, Jynge 1980b) and it would appear 
simpler to produce cardioplegia with solutions like the one 
proposed by Hearse (197 6 ).
The second component is hypothermia caused by local 
cooling. Numerous experimental studies have shown that 
hypothermia and chemical cardioplegia complement each other 
and together ensure additive tissue protection (Hearse et al 
1980, Jynge 1980a, Preusse et al 1979) .
When the optimally formulated CPS is used during 
cardioplegia, myocardial deterioration is primarily due to 
MI/R injury. With greater understanding about the 
mechanisms involved in the MI/R damage, it should be 
possible to prevent or at least delay some of these critical 
changes using carefully designed interventions. Several 
protective interventions have been incorporated 
experimentally and/or clinically in cardioplegic procedures. 
These possibilities include the following; (a) Adding 
glucose and insulin or intermediates plus alternate 
substrates of oxidative metabolism to stimulate the 
anaerobic energy production (Lolley et al 1974, Teoh et al 
1990, Rousou et al 1986). (b) Supplying of ATP and creatine
phosphate (Hearse et al 1976). (c) Buffering with
bicarbonate to combat acidosis of anaerobic glycolysis 
during ischemia (Jynge et al 1981, Buckberg 1979). 
Experimental evidence suggests that the optimum pH during
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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cardioplegia is alkaline (7.9-8.1). (d) Providing mannitol
or other agents to counter cell swelling (Goto et al 1991). 
(e) Including ion channel blockers such as the calcium 
channel blockers, verapamil and nifedipine (Rodd-Nicholson 
et al 1978, Clark et al 1977), and beta blockers (Magee et 
al 1979). (f) Adding several anaesthetic agents such as
procaine (Kay et al 1978). In addition to inducing 
electromechanical arrest, procaine is thought to stabilize 
cell membranes. (g) Inclusion of free radical scavengers in 
CPS (Bando et al 1988). (h) Inclusion of oxygen to maintain
aerobic energy production. At the present time both 
oxygenated crystalloid CPS and blood have been used 
clinically to minimize the oxygen debt arising during 
ischemic arrest (Bleese et al 1978, Buckberg 1979). The 
blood cardioplegic technique uses the blood as a vehicle of 
cardioplegic agents and oxygen. In 1978, Follette et al 
reported their findings on blood cardioplegia in animals and 
humans. They showed that mixing cool cardioplegic solution 
with autologous blood allowed prolonged aortic clamping to 
be accomplished in the animal experiments and resulted in 
postoperative recovery in patients compared with unmodified 
blood. Other groups compared the blood cardioplegia with 
crystalloid cardioplegia in laboratory experiments and 
clinical trials (Engelman et al 1980, Feindel et al 1984, 
Fremes 1984). Blood cardioplegia provided better myocardial 
protection than did crystalloid cardioplegia. As a kind of
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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oxygen carrying vehicle, perfluorocarbons have been employed 
as cardioplegic adjuvants and have improved recovery of 
cardiac function (Flaherty et al 1984, Rousou et_ a_l 1982, 
Hicks et al 1983, Ranter 1981). PFCs have increased oxygen 
solubility at low temperature (Naito and Yokoyama 1978). 
After Magovern et al (1982) indicated that blood failed to 
deliver significant amounts of oxygen to protect myocardium 
at lower temperatures, perfluorocompounds as a means of 
oxygenating crystalloid cardioplegic solutions became more 
appealing. Novick et al (1985) compared the protective 
effect of crystalloid, blood and Fluosol-DA cardioplegia on 
hypertrophied pig myocardium. They concluded that Fluosol- 
DA cardioplegia was the most effective.
4. Perfluorocarbons
Perfluorocarbons (PFCs) are predominantly comprised of 
carbon and fluorine. They may contain other atoms such as 
nitrogen, oxygen and bromide (Yokoyama et al 1983). PFCs 
are chemically inert, insoluble in other materials and 
resistant to thermal and radiation damage. They are good 
solvents for gases. Approximately 40 ml of oxygen can 
dissolve in 100 ml of most PFCs and CO2 is at least twice as 
soluble as oxygen (Sargent and Seffle 1970). These 
properties of PFCs make them potentially useful for a 
variety of biological purposes, such as gas transport. One 
well-known application is as a blood substitute. PFCs may
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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be gases, liquids or solids. For use in blood substitute 
preparations, liquid PFCs are preferred. Because they are 
hydrophobic, it is necessary to emulsify them for 
intravenous use and organ perfusion. Presently, the most 
extensively used emulsifying agents are Pluronic F 6 8  and 
various phospholipids (Geyer 1988) . Emulsions which are 
used as blood substitutes must have a suitable vapor 
pressure and short retention time in tissue. Only a small 
number of PFCs are currently viable candidates for 
biological use and most have been proven unsatisfactory 
(Geyer 1988). PFCs exert no osmotic or oncotic pressure. 
Electrolytes or plasma volume expanders must be added to 
circumvent this deficiency (Alexander et al 1975).
The solubility of O 2 and CO 2 in liquid PFCs makes them 
well suited to carry oxygen from the lungs to other tissues 
and to transport CO 2 from tissues to the lungs (Sloviter et 
al 1969) . Animal research with PFCs as blood substitutes 
has produced good results (Geyer 1975) and their initial 
clinical application has been successful (Mitsuno 1988, Chen 
and Yang 1988) . Bloodless animals perfused with PFC 
emulsion survive and rapidly produce new plasma proteins and 
red cells (McCoy 1988). Geyer (1975) also demonstrated that 
rats, perfused with PFC, tolerated toxic levels of carbon 
monoxide. In contrast to red blood cell, PFCs can 
simultaneously carry oxygen, carbon monoxide and carbon 
dioxide. The oxygen solubility of PFCs is not affected by
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
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carbon monoxide.
Although PFCs are inert compounds and usually nontoxic, 
they can produce some side effects when administered 
intravenously for a fairly long period of time. The major 
adverse effects relate to excessive deposition in the liver 
and spleen. Anaphylactoid reactions, which include 
complement activation, hypotension, leukopenia, and other 
changes in the immune system, have also been observed (Clark 
et al 1973, Caiazza et al 1988, Zhang et al 1988, Lowe and 
Hollands 1988) . Some perfluorinated compounds are 
peroxisome proliferators and act as a positive modulator of 
hepatocarcinogenesis. Abdellatif et al (1991) determined 
that perfluorooctanic acid can significantly increase the 
incidence of hepatocellular carcinoma in response to 
carcinogenic agents.
PFC emulsions have been successfully used to preserve 
organs such as kidney, liver and heart for transplantation 
(Fuchinoue et al 1985, Baba et al 1988, Biro et al 1989, 
Tomera and Geyer 19 82).
Another important application of PFCs is as an 
oxygenating agent. Not only do the PFC containing products 
have excellent 0 2 -carrying capacity, they also release O 2 at 
a higher partial pressure than would occur with a plasma/red 
blood cell mixture. Since PFC particles are approximately 
1/70 the size of red blood cells, they can penetrate past 
partial vascular obstructions into areas that are
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inaccessible to red blood cells. PFC particles load and 
unload O 2 faster than do erythrocytes. The lower viscosity 
of PFC emulsions facilitates a higher flow into tissues. 
(Fischer et al 1986, Geyer, 1975).
Hypoxia limits tumor radiotherapeutic efficacy because 
oxygen is a potent radiosensitizer. At usual 
radiotherapeutic levels, only a small amount of damage can 
be produced by direct interactions between radiations such 
as X-ray or gamma rays and biological molecules. Most 
critical damage is produced indirectly by a variety of 
radicals and other chemically reactive species which are 
generated through chemical reactions in the tissue initiated 
by radiation. Oxygen participates in these chemical 
reactions leading to radiation damage. Solid tumors have a 
poor blood supply and consequently contain insufficient 
oxygen tension to allow efficient radiotherapy (Rockwell 
1988). The beneficial rheological characteristics of PFC 
emulsions (i.e. small particle size and low viscosity) allow 
them to increase tumor oxygenation and improve radiotherapy 
(Teicher and Rose 1984).
PFC emulsions have also been used to treat brain 
ischemia. Because the brian is so rapidly affected by 
hypoxia, it is crucial to replenish the supply of O 2 as 
rapidly as possible. Both experimental and clinical studies 
have demonstrated the efficacy of these blood substitutes in 
brain ischemic tissue (Clark et al 1989, Chen et al 1988) .
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MI/R injury is initiated by insufficient oxygen 
supply. PFCs which possess effective oxygen carrying ability 
and therefore can delay hypoxia have been obvious candidates 
to rescue ischemic hearts. Glogar et al (1981) demonstrated 
that PFC preparations markedly reduced the infarcted area in 
a regionally ischemic canine heart model when they partially 
replaced the blood and the animals breathed 1 0 0 % oxygen.
Rude et al (1982) indicated that PFC emulsions improved 
oxygen supply to the myocardium in a similar regional 
ischemic model. Based on the isolated rabbit heart global 
ischemic model, Parrish et al (1984) argued that the 
benefits shown by PFCs when used during reperfusion could be 
attributed to their superior rheological properties. The 
special rheological characteristics of PFCs may also be one 
of the mechanisms by which they limit ischemic damage when 
used during occlusion episodes (Glogar 1981). Bajaj et al 
(1989) demonstrated that myocardial preservation by PFCs was 
associated with their ability to suppress the enhanced 
neutrophil margination and infiltration into myocardium 
caused by ischemia. Oxygenated perfluorochemical 
cardioplegic solutions can support aerobic metabolism and 
therefore delay depletion of high-energy phosphate during 
cardiac arrest (Rousou et al 1982, Flaherty et al 1984,
Bando et al 1988). Inclusion of PFCs in cardioplegic 
solution prevented intracellular acidosis and the 
accumulation of lactate, creatine phosphokinase and
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thiobarbituric acid reactive substances (products of lipid 
peroxidation) in the coronary effluent.
One of the most serious deficiencies of PFC blood 
substitutes is their limited oxygen carrying capacity, 
related to their low PFC content (Arlen et al 1988). For 
instance, the first commercial preparation, Fluosol-DA, 
contains only 20% (w/v). One of the brominated 
fluorochemicals, perfluorooctylbromide (PFOB), was first 
synthesized as a nontoxic contrast agent for fluoroscopy,
NMR imaging and ultrasonography. PFOB has the capability to 
form reasonably stable emulsions at higher concentrations 
than most other PFCs (Long et al 1988). A 100% (w/v) 
emulsion, which is easy to achieve, has more than four times 
the oxygen-carrying capacity of Fluosol-DA (a 20% PFC 
emulsion) (Riess 1988). Biro et al (1989) tested the 
cardioprotective effects of this novel PFC emulsion (50% 
w/w) on a modified Langendorff rat heart preparation. They 
found that after switching the perfusate from aqueous 
perfusate to PFOB emulsion, contractile performance of 
hearts was significantly higher. However, protective 
effects of this PFC emulsion have not been determined in 
MI/R injury models.
5. Tationale for These Experiments
A 100% PFOB emulsion has a very high oxygen-carrying 
capacity. MI/R injury occurs during cardioplegic processes.
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This damage is initiated by hypoxia. The hypothesis that 
oxygenated PFOB-containing cardioplegic solutions can 
prevent the decline in cardiac function associated with 
cardioplegia was tested in the modified Langendorff rat 
heart preparation.
Several mechanisms of successful interventions in MI/R 
injury exist. They include prevention of the depletion of 
ATP and endogenous free radical scavengers such as 
glutathione (GSH). Also, endogenous antioxidant enzymes 
such as superoxide dismutase (SOD), catalase (CAT), and 
glutathione peroxidase (GPD)) can be maintained or induced. 
The ability of PFOB to preserve endogenous antioxidant 
defenses and ATP levels during crystalloid cardioplegia was 
also determined in these experiments.
Although cold cardioplegia is commonly performed in 
clinical surgery, hypothermia is still controversial 
(Lessana et al 1992) . Hypothermia is an alternative way to 
protect the myocardium by slowing metabolism and 
degenerative processes. The aim of the current study was to 
define the cardioprotective effects of PFOB emulsions. 
Application of hypothermia in this research would make the 
result more difficult to interpret since there would be 
another protective factor to consider. In order to simplify 
this research, all investigation was undertaken at normal 
temperature (37°C).
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MATERIALS AND METHODS
ANIMALS AND HOUSING:
Male Sprague-Dawley rats, weighing 400-500g, were used. 
Two rats were housed together in a wire-mesh cage over wood- 
chip bedding. Purina lab chow and water were available ad 
lib during 12 hour light-dark cycles. All animals were 
allowed a minimum of 2 days acclimatization before use in 
the experiments.
REAGENTS AND DRUGS:
Drugs and reagents were obtained from the indicated 
sources. Sodium pyruvate, Tetrabutylammonium hydrogen 
sulphate (TBAHS),
Ethylenediaminetetraacetic acid (EDTA), Glutathione, reduced 
form, Glutathione reductase, B-Nicotinamide adenine 
ninucleotide, reduced form (NADH), B-Nicotinamide adenine 
dinucleotide phosphate, reduced form (NADPH), Sulfosalicylic 
acid, Triethanolamine, Diethylenetriamine-pentacetic acid 
(DTPA), 2,4-Dinitrophenylhydrazine, Pyrogallol, Triton X-100 
(Sigma Chemical Co. St Louis, Mo). Potassium chloride 
(KCl), Sodium bicarbonate (NaHCOg), Calcium chloride (CaCl), 
Sodium phosphate monobasic (KH2 PO 4 ), Potassium phosphate 
dibasic (K2 HPO 4 ) , Sodium hydroxide (NaOH), Tris (buffer), 
Acetonitrile, (Baker Chemical Co. Phillisburg, NJ).
Potassium phosphate monobasic (KH2 PO 4 ), Perchloric Acid,
22
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Hydrogen peroxide (H2 O 2 ), Hydrochloric acid (HCl) (Fisher 
Chemical. Fair Lawn, NJ). Sodium chloride (NaCl),
Magnesium sulfate (MgSO^'7 H 2 O), Sulfuric acid (H2 SO4 ), (EM 
Science, Cherry Hill, NJ). Dextrose, Potassium permanganate 
(Mallinckrodt Chemical Works, St Louis, Mo). Magnesium 
chloride (MgCl2 '6 H 2 O) (Allied Chemical & Dye Corporation,
New York, N J). 5,5'-Dithiobis(2-nitrobenzoic acid (DTNB)
(ICN Biochemicals, Cleveland, OH) . 2-Vinylpyridine (Aldrich 
Chemical Company, Inc. Milwaukee, WIS). Pluronic F 6 8  (BASF 
Wyandotte Corporation, Wyandotte, Michigan).
Perfluorooctylbromide (PFOB) (PCR Incorporated, Gainesville, 
Florida).
EXPERIMENTAL PROTOCOL:
1. Cardioplegic reperfusion injury:
Male Sprague-Dawley rats, weighing 400-500g, were 
anesthetized with sodium pentobarbital ( 1 0 0  mg/Kg i .p .), 
intubated to maintain ventilation during cardiac procedures, 
and heparinized. The aorta was isolated and a cannula 
inserted. Hearts were perfused with modified Krebs-Henseleit 
(KH) solution (NaCl 112 mM; KCl 5 mM; MgSO^"7 H 2 O 1.2 mM; 
KH 2 PO 4 1 mM; NaHCO]
25 mM; Dextrose 11.5 mM; Na Pyruvate 2 mM; CaCl-2 H 2 0  1.2 5 
mM), aerated with 95% 0 2 -5 % CO 2 gas mixture, at a pressure 
of 80 mmHg and a temperature of 37°C. Hearts were suspended 
in a heated muscle bath filled with KH solution. The left
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atrium was removed to allow the insertion of a balloon 
cannula into the left ventricle. The balloon cannula was 
connected to a pressure transducer to monitor heart rate and 
left ventricular developed 
pressure (LVDP).
Hearts were allowed to equilibrate for 15 minutes 
before the balloon was inflated to 5 mmHg LVDP. After 2 0 
minutes, coronary flow (CF), heart rate (HR), and LVDP were 
recorded. A one-ml sample of perfusate was obtained for 
determination of lactate dehydrogenase (LDH) activity. LDH 
was determined with a kit supplied by Sigma (Procedure 
No.500) as described in Appendix A. LDH release is 
expressed as Berger-Broida (B-B) units/ml. Cardiac function 
estimated as double product (DP) was calculated as (HR x 
LVDP /lOOO). Hearts were switched to another reservoir 
which contained the St. Thomas' Hospital Cardioplegic 
Solution No.2 (CPS) (NaCl llOmM; KCl 16mM; MgCl 2 *6 H 2 0  16mM; 
CaCl2 '2 H 2 0  1.2mM; NaHCO] lOmM), aerated with 95% 0 2 -5 % CO 2 
gas mixture. After perfusion for 3 minutes, the flow of CPS 
was shut off and the KH in the bath was replaced by the same 
cardioplegic solution. After a 30 minute global ischemia, 
the hearts were reperfused by KH and the CPS in the bath was 
replaced with KH. Following a 3 0-minute period of 
reperfusion, values for HR, LVDP, CF, DP and LDH activity 
were determined again.
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2. PFOB emulsions:
Emulsification of PFOB was accomplished by adding the 
appropriate weight of the compound to the appropriate volume 
of CPS containing 2.7% Pluronic F- 6 8 , a surfactant. The 
mixtures were sonicated with a Branson Sonifier resulting in 
a cloudy, but stable, emulsion. The emulsions were aerated 
with 95% 0 2 - 5 % CO 2 for 15 minutes before use. Hearts 
exposed to PFOB were treated the same as control hearts, 
except that they were subjected to a single infusion of PFOB 
emulsion to fill the coronary circulation and then immersed 
in the PFOB emulsion. Values for HR, LVDP, CF, DP and LDH 
activity were again determined prior to cardioplegia and
after 30 minutes of reperfusion.
3. Tissue preparation:
At the end of the 3 0 minute reperfusion period, left 
ventricular tissue was rapidly frozen and stored in liquid 
nitrogen. Less than 1 week later ATP and intracellular 
antioxidant assays were performed with the wet tissue. A 
control group of hearts were frozen just prior to ischemia 
for determination of preischemic values. Contents of the 
substances and activity of enzymes were expressed per gram 
of wet tissue weight.
4. Assays:
The detailed procedures for intracellular substance 
assays are described in the Appendix A.
a. ATP was measured by counter ion HPLC as modified from the
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method of Sellevold et al (1986). ATP was extracted from 
tissue with 0.42M perchloric acid. The perchloric acid was 
then neutralized with 1.0 M KOH in the presence of an 
indicator, 0.1% chlorphenol red. A C-18 reverse phase 
column was used. The mobile phase was a degassed 10% 
acetonitrile : 9 0% KH 2 PO 4 mixture. ATP standard solutions 
were used to establish the standard curve for quantifying 
the ATP level in tissue.
b. Glutathione (GSH) and crlutathione disulfide fGSSG^ were 
determined enzymatically by the DTNB-GSSG reductase 
recycling
procedure (Anderson, 1985). The samples were deproteinized 
by treatment with 5% 5-sulfosalicylic acid. GSH was oxidized 
by 5,5'-dithiobis(2-nitrobenzoic acid) (DTNB) to GSSG with 
stoichiometric formation of 5-thio-2 -nitrobenzoic acid 
(TNB). GSSG was rapidly reduced by GSSG reductase and NADPH 
which were added in the reaction mixture. The rate of TNB 
formation was followed at 412 nm and was proportional to the 
sum of GSH and GSSG present. GSSG was measured by masking 
GSH with 2-vinylpyridine before running the assay. GSH was 
then calculated by subtracting the GSSG from the total 
glutathione.
c. Glutathione peroxidase (GPD) was determined by continuous 
monitoring of GSSG formation in the reaction mixture (Flohe 
and Gunzler 1984). GSH is oxidized by GPD to GSSG. The GSSG 
is then reduced by an excess of glutathione reductase to
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maintain a constant level of GSH. The rate of concomitant 
oxidation of NADPH is proportional to GPD activity and can 
be monitored spectrophotometrically.
d. The total amount of suoeroxide dismutase CSOD) was 
assayed by the pyrogallol auto-oxidation method (Maestro and 
McDonald 1985). This assay is based on the ability of SOD 
to scavenge superoxide anion radicals. Removal of these 
molecules decreases the overall rate of pyrogallol 
autoxidation. The tissue samples were homogenized in 10 mM 
potassium phosphate buffer supplemented with 3 0 mM KCL.
e. Catalase CCAT) samples were prepared in the same buffer 
used for SOD. Prior to the determination, ethanol and 
Triton X-100 were added into the sample to increase the 
observable catalase level by decomposing the inactive 
complex of catalase with H 2 O 2 or directly activating the 
enzyme. Samples were added to a standardized amount of H 2 O 2 
solution. The H 2 O 2 which remained in the reaction mixture 
after 3 minutes was titrated with potassium permanganate.
The catalase activity was inversely proportional to the 
amount of H 2 O 2 left in the reaction mixture (Cohen et al 
1970).
5. Statistics;
ANOVA and Newman-Keuls procedures were employed to 
determine significant differences among multiple treatment 
means (Steel and Torrie 1960). (p < 0.05 = significant 
difference)
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RESULTS
Preliminary studies showed that a three minute coronary 
perfusion with CPS stopped all hearts. The following 3 5 
minutes of ischemia and an additional 3 0 minutes of 
reperfusion with KH produced significant decreases in left 
ventricular contractile function (LVDP and Double Product) 
and coronary flow. A significant increase in extracellular 
LDH accumulation also occurred. No significant changes in 
heart rate were noted. The surfactant control (2.7%
Pluronic F - 6 8  in CPS) produced similar results (Figs. 1-5). 
We also observed that the ischemic time was very critical 
since 3 0 and 3 8 minutes of ischemia produced minimal and 
maximal injury, respectively.
Statistical analysis indicated no significant between- 
group differences for preischemic ventricular contractile, 
coronary flow values and extracellular LDH levels. Both 
100% and 50% PFOB emulsions prevented the decline in left 
ventricular contractile function (LVDP, Double product) seen 
in control treatments. The 25% PFOB did not demonstrate 
this protection (Figs. 2 and 3). However, the decrease in 
coronary flow associated with reperfusion injury was not 
affected by any of the PFOB emulsions (Fig. 4). Heart rate 
was not altered by the PFOB emulsions (Fig. 1). The 
elevation in extracellular LDH was not significantly reduced 
by the 100% PFOB emulsion even though contractile function 
was sustained by this high concentration of the
28
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emulsion (Fig. 5).
ATP, glutathione and endogenous antioxidant enzymes 
were only investigated in control and 100% PFOB treated 
hearts. Cardioplegia-induced ischemia and reperfusion 
reduced the tissue ATP concentration. The 100% PFOB was 
able to maintain a normal ATP level. There is no 
significant difference in ATP content between preischemic 
tissue and postischemic tissue treated with 100% PFOB 
(Fig. 6 ).
Table 1 shows that cardioplegia followed by reperfusion 
depleted the total glutathione and GSH levels in the 
myocardium, while the GSSG was not significantly decreased. 
The 100% PFOB prevented the loss of the total glutathione 
pool inside the cells. However, while there was no 
significant difference in GSH values between the preischemia 
control and the 100% PFOB treated group, the latter had less 
total glutathione content than the preischemic hearts.
The myocardial antioxidant enzymes GPD, CAT, and SOD 
were not significantly altered by the cardioplegia-induced 
MI/R injury. The 100% PFOB failed to modify any of these 
intracellular antioxidant defenses (Table 2).
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Fig. 1. Pre-Ischemia = preischemic value. Post-Ischemia = 
value after 35 minutes of ischemia and following 30 minutes 
of reperfusion. PFOB = perfluorooctylbromide emulsions in 
cardioplegic solution administered during time of ischemia. 
Pluronic F-68 represents a control containing 2.7% of this 
surfactant. Bars represent mean ± SEM. Number of rats used 
is given above the bars.
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Fig. 2. Terms are the same as for Fig. l.
* = significantly different from its respective preischemia 
value. ** = significantly different from its respective
preischemia value and from the control value, (p < .05 = 
significant difference).
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Fig. 3. Terms and marks are the same as for Fig.1 and Fig.2. 
Double product = (heart rate x left ventricular developed 
pressure)/lOOO.
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Fig. 4. Terms and marks are the same as for Fig.1 and Fig.2.
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Fig. 5. Terms and marks are the same as for Fig.l and Fig.2.
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EFFEC T OF PFOB ON ATP LEVELS
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Fig. 6. Pre-Isc = preischemic value. Post-isc control = 
control value after 3 5 minutes of ischemia and following 30 
minutes of reperfusion. Post-isc 100% PFOB = value after 
ischemia and reperfusion with administration of 100% PFOB 
emulsion in cardioplegic solution during ischemia. Bars 
and sample size are given in the same way as for Fig. 1. *
= significantly different from all other values (p < .05) .
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Table 1. Effects of PFOB on Glutathione Levels in Heart 
Tissue
Pre-Ischemia
Control
Post-Ischemia
Control
Post-Ischemia 
100% PFOB
GSH
(umol/g tissue)
1.44 ± 0.060 
(n = 1 1 )
0.79 ± 0.0803 
(n = 6 )
1 . 2 2  ± 0 .0 7 b 
(n = 6 )
GSSG
(umol/g tissue)
0.23 ± 0.012 
(n = 1 1 )
0.19 ± 0.009 
( n = 6 )
0.19 ± 0.016 
(n = 6 )
GSSG + GSH 
(umol/g tissue)
1.57 ± 0.050 
(n = 1 1 )
0.95 ± 0.0723 
(n = 6 )
1.41 ± 0.05?3,b 
(n = 6 )
All values are Mean ± SEM.
^ Significantly different from preischemic value, 
b Significantly different from postischemia control value.
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Table 2. Effects of PFOB on the Activity of Myocardial 
Antioxidant Enzymes
Pre-Ischemia
Control
Post-Ischemia
Control
Post-Ischemia 
100% PFOB
GPD
(umol NADPH 
oxid/min/g tissue)
20.38 ± 0.65 
( n = 8 )
17.73 ± 0.87 
(n = 6)
18.84 ± 1.52 
(n = 6)
CAT
(k X 10 ”2)
2.95 ± 0.15 
(n = 6)
2.37 ± 0.24 
(n = 6)
2.83 ± 0.09 
(n = 6)
SOD
(units/g tissue)
257.9 ± 25.1 
(n = 6)
252.8 ±17.4 
(n = 6)
241.7 ± 26.0 
(n = 6)
GPD = Glutathione peroxidase, CAT = Catalase, SOD = 
Superoxide dismutase.
All values are Mean ± SEM.
Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.
DISCUSSION
The control data indicated that this cardioplegic model 
caused reproducible and measurable MI/R injury simulating 
that induced by hypothermic cardioplegia. Shlafer et al 
(1982) tested cardioprotective effects of several solutions 
administered during ischemia in an isolated rabbit heart 
preparation. They demonstrated that following a 2 hour 
hypothermic cardioplegia (27°C) and a 1 hour reperfusion 
with oxygenated physiological saline solution, hearts 
incurred significant decreases in LVDP, left ventricular 
compliance, the maximum rate of left ventricular pressure 
development (dP/dt) and coronary flow. No differences in 
heart rates were noted. LDH released during reperfusion was 
also significantly increased. Similar changes in these 
important indicators of cardiac function were also found by 
Ledingham et al (1990) in their hypothermic cardioplegic 
model with isolated rat hearts, in which the same CPS as 
used in this laboratory was employed to induce ischemia (4 
hours at 4°C).
After MI/R, myocardial tissue lost 72.8% of it 
preischemic ATP content (postischemia 154 ± 16.2 vs 
preischemia 546 ± 62 nmol/g wet tissue). These data are in 
agreement with the findings of other investigators who 
employed long hypothermic cardioplegia to induce MI/R damage 
(Rousou et al 1986, Wyatt et al 1989). The decline of ATP 
content has been noted in almost every ischemic and
38
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reperfused model. There is good correlation between 
myocardial ATP level and left ventricular function (Flaherty 
et al 1984, Ledingham et al 1990, Ferrari et al 1985). All 
this evidence indicates that this normotherraic cardioplegia- 
induced model of MI/R injury is similar to that produced by 
hypothermic cardioplegia in terms of changes in myocardial 
functional and biochemical parameters. However, it is 
superior to the others in terms of simplifying procedures 
and shortening experimental time. Additionally, a variety 
of levels of hypothermia (4°C— 3 0°C) has been applied by 
different authors and this variability makes comparisons 
difficult. It is well established that homogeneous 
distribution of cooling during cardioplegia is difficult to 
achieve in patients with coronary artery stenoses or 
occlusions (Menash et al 1988). Under these situations, the 
myocardium is not entirely cooled during cold cardioplegia. 
Warm cardioplegia is currently used in some medical 
facilities for myocardial protection during open heart 
procedures (Lessana et al 1992). This model does mimic some 
clinical practices. The protective effect of PFOB emulsions 
indicates that this model may be used to evaluate the 
efficacy of various treatments which might significantly 
enhance the cardioprotection provided by cardioplegia.
The PFOB emulsions produced a dose-dependent protection 
against MI/R injury as measured by ventricular contractile 
function. Both 100% and 50% PFOB significantly increased
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the extent of recovery of cardiac function while the effect 
of 25% PFOB could not be distinguished from the control. 
These results support the hypothesis that enhanced delivery 
of oxygen to the heart during ischemic arrest can improve 
myocardial preservation.
ATP levels and DPs were not significantly decreased 
after hearts were arrested with CPS containing 100% PFOB and 
reperfused with KH. Therefore, the high correlation between 
the preservation of cardiac function and maintenance of ATP 
observed by others (Godin et al 1989, Sellevold et al 1986) 
was verified in the current study. There is good 
experimental evidence that oxygenated PFC emulsions can 
enhance the intramyocardial oxygen tension (Rude et al 1982, 
Novick et al 1985). This maintains aerobic metabolism which 
is otherwise lost during ischemia. PFOB emulsion appeared 
to be capable of maintaining sufficient aerobic metabolism 
to prevent ischemia-induced loss of ATP. A large data base 
supports the conclusion that other PFC emulsions can retard 
high-energy phosphate decline during ischemia (Rousou et al 
1982, Flaherty et al 1984, Bando et al 1988). When Rude et 
al (1982) and Kanter et al (1981) compared PFC and blood 
cardioplegia, they proposed that the beneficial effects are 
not only due to PFC emulsion's high oxygen transporting 
ability, but also due to the augmented myocardial O 2  
consumption in the ischemic hearts receiving oxygenated PFC 
emulsions (i.e. the amount of oxygen which can be actually
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taken up by the myocardium is high). This may occur as a 
consequence of faster unloading rate of oxygen and 
significant rheological features such as smaller particle 
size and lower viscosity (Fisher et al 1986). Our study did 
not address these possible mechanisms.
Carbon dioxide has about 2.5 times higher solubility 
than oxygen in PFCs (Geyer 1988). During ischemia the 
relatively high pressure of CO2 in the myocardium partially 
accounts for the tissue damage (Rude et al 198 2). PFOB 
could absorb this byproduct of ischemia and therefore 
diminish the tissue damage.
PFOB emulsions failed to significantly alter the 
decrease in coronary flow that followed reperfusion. This 
evidence does not seem to correspond to the protection of 
contractile function by highly concentrated emulsions. It 
has been reported previously that PFC emulsion-perfused 
hearts had decreased coronary flow compared with those 
receiving normal physiological solution (Rahamathulla et al 
1985). The increased viscosity of PFC emulsions may account 
for this event (O'Neill et al 1981). Menash et al (1988) 
indicated that applying a PFC emulsion during cardioplegia 
diminished postischemic coronary flow even though 
crystalloid cardioplegic solution did not exhibit decreased 
coronary flow after reperfusion in their isolated rat heart 
model. The mechanism of this phenomenon has not been 
determined. In our case, one possibility would be that PFOB
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emulsions failed to modify the vascular damage caused by 
MI/R.
GSH, a cofactor of GPD, has a critical role in the 
protection of myocardium against oxidative damage either by 
inactivation of lipid peroxides or by eliminating hydrogen 
peroxide. The depletion of tissue GSH has been referred to 
as a direct manifestation of myocardial oxidative injury 
(Guarnieri et al 1980). Thirty five minutes of cardioplegia 
and reperfusion induced a reduction of the tissue GSH/GSSG 
ratio. This reduction results from a significant decline in 
GSH with GSSG unchanged. This does not agree with other 
reports and is difficult to interpret. Increased oxidative 
stress leads to the depletion of GSH, which should in turn 
cause accumulation of GSSG in cell. However, there was a 
marked release of LDH from the damaged tissue. This implies 
that the cell membrane was disrupted and GSSG may have been 
lost from the cells into the coronary effluent upon 
reperfusion. Ferrari et al (1985) have shown that 
reperfusion of severely injured ischemic hearts causes a 
marked and sustained release of GSH and GSSG as result of 
peroxidation of cellular membranes. The percentage of GSSG 
release is higher than that of GSH,
PFOB retarded the loss of intracellular GSH that 
normally occurs in MI/R. This indicates that the 
maintenance of oxygenation during cardioplegic arrest 
prevents oxidative stress upon readministration of
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oxygenated physiological perfusate. Formation of free 
radicals is initiated during myocardial ischemic phase (Rao 
et al 1983) and GSH is depleted before reperfusion (Ceconi 
et al 1988). PFOB may also reduce the free radical 
reactions caused by lower oxygen tension when the hearts 
were ischemic. However, the present experiments have not 
confirmed this mechanism. Another contribution to this 
event could be preservation of the cellular membrane. 
Decreased lipid peroxidation in PFOB treated hearts could 
help maintain the cellular membrane integrity and prevent 
the leakage of GSH from the cell. ATP plays a critical role 
in membrane function and integrity (Burton et al 1980, 
Jennings et al 1978). The high ATP level in PFOB treated 
hearts may also contribute to this protection.
The activities of the antioxidant enzymes (SOD, GPD, 
CAT), which some investigators repeatedly demonstrated to be 
lessened after MI/R injury (Guarnieri et al 1980, Meerson ^  
al 1982, Julicher et al 1984), were not affected by MI/R in 
this model. However, there are numerous papers that present 
unchanged values or even increased enzyme activity after the 
damage (Arduini et al 1988, Godin et al 1989, Shlafer et al 
1987). These discrepancies may relate to differences in the 
duration of ischemia and reperfusion and the use of 
different animal models. In this case, the cardioplegic 
solution applied during the ischemic episode may contribute 
to the inability to detect any variation. Although
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protective, PFOB was not associated with any significant 
effect on these enzymes and did not induce these enzymes in 
the tissue. This implies that the mechanism of the 
protection by PFOB in this model may be due to its ability 
to transport gases.
LDH release was not significantly diminished by the 
100% PFOB although this concentration provided 
cardioprotection in terms of mechanical and biochemical 
parameters. LDH release did not correlate well with cardiac 
function. This lack of correlation has been found in 
previous studies in our laboratory and by other 
investigators (Grover and Sleph 1989, Irem et al 1991).
In conclusion, the results have shown that this 
normothermic cardioplegia-induced MI/R injury model is 
similar to the other MI/R models and can be used to study 
the mechanisms and treatment of MI/R damage. Enhanced 
oxygen delivery during cardioplegia can diminish MI/R 
injury. The data suggest that PFOB enhances oxygen delivery 
and might be used to reduce damage that occurs during 
cardiac surgery and organ preservation.
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APPENDIX A 
ASSAY PROCEDURES
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LACTATE DEHYDROGENASE ACTIVITY
Reagents:
Na pyruvate solution: 100 mg/L
NADH solution (prepared immediately before use): lOO mg/ml 
Color reagent: 200 mg/L of 2,4-Dinitrophenylhydrazine in
1 N HCl 
NaOH solution: 0.4 N,
Instruments :
37°C water bath
Bausch & Lomb Spectronic 21
Procedure :
1). 1 ml of Na pyruvate solution and 10 ul of NADH solution 
were pipetted into each of two labelled test tubes 
(blank and sample), the tubes were placed in the 37°C 
water bath for 5 minutes.
2). 0.5 ml of sample or blank (Krebs-Henseleit solution) 
were added and mixed gently. Timer was started and the 
tubes were kept in the 37°C water bath.
3). After exactly 3 0 minutes of incubation, the tubes were 
removed from water bath and 1 ml of color reagent was 
added to each tube. Tubes were mixed thoroughly and 
allowed to remain at room temperature for 2 0 minutes.
4). 10 ml of NaOH solution were added to each tube and 
mixed well.
5) . Between five and thirty minutes after adding the NaOH
solution, absorbance was read and recorded with water
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as reference at a wavelength of 52 5 nm.
6 ). The LDH activity in the sample was expressed by as B-B 
units/ml. B-B units/ml = (O.D.ga^pje - O-D.^iank) x 
1200.
ADENOSINE TRIPHOSPHATE 
Reagents;
Perchloric acid: 0.42 mM 
KOH solution: 1 M
pH indicator: 0.1% chlorphenol red
Phosphate buffer: 215 mM KH 2 PO 4 and 2.3 - 8 mM
tetrabutylaraonium hydrogen sulphate 
(TBAHS), pH 6.3 
Mobile phase: 90% phosphate buffer: 10% acetonitrile 
Instruments :
lEC B-20A Centrifuge 
Milton Roy HPLC system 
Procedure :
1) . Frozen tissue was quickly removed from liquid nitrogen
and homogenized in perchloric acid solution (10% W/V) 
on ice.
2). The homogenate was spun for 10 minutes at 10,000 rpm in
the chilled (1 - 3 °C) centrifuge.
3) . The supernatant was transferred to a clean tube and KOH
solution was added to precipitate and neutralize 
perchloric acid in the presence of the indicator.
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4). The mixture was filtered through a microfilter and kept 
on ice until 20 ul of sample was injected into the HPLC 
system.
5). The mobile phase was degassed before use. The flow 
rate was maintained at 0.7 ml/min and the 
spectrophotometer was set at 2 59 nm.
6 ). Different ATP standard solutions were prepared with the 
same procedure and used to establish the standard curve 
for determination of the ATP in the tissue samples.
GLUTATHIONE (GSH) AND GLUTATHIONE DISULFIDE (GSSG)
Reagents :
5-Sulfosalicylic acid solution; 5%
Stock buffer: 143 mM KH 2 PO 4 and 6.3 mM EDTA, pH 7.5
NADPH solution: 0.248 mg/ml in stock buffer. Stored at ice
cold and prepared daily 
5,5'-Dithiobis(2-nitrobenzoic acid) (DTNB): 6 mM DTNB was
prepared in the stock buffer and 
stored frozen. The stork buffer was 
thawed before use and kept on ice . 
GSSG reductase: The stock enzyme was diluted to 266 U/ml
with stock buffer and stored on ice during
the experiment.
GSH standards: Standards were diluted daily in 5-
sulfosalicylic acid from a frozen 1 6  mM 
stock solution which was prepared weekly in
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5-sulfosalicylic acid
2-Vinylpyridine
Triethanolamine
Instruments :
lEC B-2 0A Centrifuge
Bausch and Lomb Spectronic 600 with constant temperature 
cuvette compartment
Procedure:
1). Tissue samples were homogenized on ice with 5-
sulfosalicylic acid solution (10% W/V). The homogenate 
was centrifuged for 10 minutes at 10,000 rpm in the 
refrigerated (1-3°C) centrifuge.
2). For the total amount of glutathione assay, the 
supernatant was ready to use in the following 
procedure. For GSSG measurement, 0.5 ml of supernatant
was mixed with 10 ul 2-vinylpyridine and 1 drop
(approximate 30 ul) of triethanolamine . The final pH
of the mixture was 6-7. The mixture were allowed to 
stay at room temperature for 60 minutes.
3). 700 ul of NADPH, 100 ul of DTNB and 175 ul of water 
were pipetted into a cuvette. The mixture was 
prewarmed at 3 0°C for 10 minutes in the constant 
temperature cuvette compartment of the spectrometer.
4). 25 ul of sample or standard solution was added.
5). 20 ul of glutathione reductase was added with mixing to
initiate the reaction. Times were recorded when the
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absorbance was 0.5, 1.0, 1.5, and 2.0 at 412 nm.
6 ). The reaction rate (AO.D./min) was estimated from the
slope of the regressed line in which absorbance (O.D.) 
was plotted against time. The amount of GSH 
equivalents was determined from a standard curve in 
which the GSH equivalents present in the standard 
solutions were plotted against the reaction rate.
GLUTATHIONE PEROXIDASE (GPD) ACTIVITY
Reagents :
Phosphate buffer; 0.1 M KH 2 PO 4 , 1 mM EDTA, pH 7.0 
GSSG reductase: 2.66 U/ml dilution in phosphate buffer
from the stock enzyme 
GSH standard: 10 mM GSH in water 
NADPH solution: 1.5 mM NADPH in 0.1% NaHCOg 
H 2 O 2 solution: 1.5 mM H 2 O 2 in water
Instruments :
IEC B-2 0A Centrifuge
Bausch and Lomb Spectronic 600 with a constant temperature 
cuvette compartment
Procedure:
1). Tissue samples were homogenized in phosphate buffer (1 %
W/V) on ice and then spun for 10 minutes at 10,000 rpm
in the refrigerated (1-3°C) centrifuge.
2). 500 ul of buffer, 100 ul of GSSG reductase, 100 ul of
GSH standard and 100 ul of sample or phosphate buffer
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as blank were pipetted into a cuvette. The mixture was 
preincubated at 37°C for 10 minutes in the constant 
temperature cuvette compartment of the 
spectrophotometer.
3). 100 ul of NADPH was added into the cuvette and mixed by
inversion. The mixture was incubated for another 3 
minutes.
4). 100 ul of H 2 O 2 was pipetted into the mixture and
quickly mixed to initiate the reaction. The absorbance 
at 365 nm was recorded for 5 minutes.
5). The rate of change of absorbance (AO.D./min) was 
estimated from the slope of the regressed line in which 
absorbance (O.D.) was plotted against time. The change 
of absorbance was caused by the oxidation of NADPH in 
the reaction mixture and therefore the rate of NADPH 
oxidation (mol NADPH oxidized/min) was calculated from 
the AO.D./min using the appropriate extinction 
coefficient (E=A/L*C). The coefficient was measured by 
reading the absorbance of NADPH standard solution with 
the same cuvette and spectrophotometer. The GPD 
activity in samples was calculated from the difference 
of the mol NADPH oxidized/min between the sample and 
blank.
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SUPEROXIDE DISMUTASE (SOD) ACTIVITY
Reagents:
Phosphate buffer: 10 itiM K 2 HPO4 and 30 mM KCl pH 7.4 
Tris buffer: 50 mM Tris (buffer), 1 mM diethylenetriamine 
pentacetic acid (DTPA), pH 8.2 (The solution 
is aerated by stirring vigorously at room 
temperature for 2 0  minutes before use) 
Pyrogallol: 24 mM in 10 mM HCl.
Instruments :
Branson Sonifier 450 
lEC B-2 0A Centrifuge 
Bausch & Lomb Spectronic 21
Procedure:
1). The tissue sample was sonicated for 1 minute at an 
output setting of 5 in ice-cold phosphate buffer. The 
homogenate was then centrifuged at 1 0 , 0 0 0  rpm for 1 0  
minutes in the refrigerated (l-3°c) centrifuge. The 
supernatant was used for determination of enzyme 
activity .
2). 3 ml of Tris buffer were added to 30 ul of supernatant 
in a cuvette. The reaction was initiated by adding 2 5 
ul of pyrogallol solution. The change of the 
absorbance at 420 nm, caused by the formation of the 
oxidized pyrogallol, was recorded for 2-3 minutes.
3). A blank was run using the Tris buffer plus pyrogallol.
4). The autoxidation rate (AO.D./min) was estimated from
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the slope of the regressed line in which absorbance was 
plotted against time. The percentage of the 
autoxidation rate inhibited by the enzyme sample was 
calculated as: %inhibation = (AO.D.biank “
A O .D .sample)/ ♦ D •blank ^ 100%. One unit of SOD 
activity was defined as the amount which inhibits the 
rate of autoxidation by 50%.
CATALASE (CAT) ACTIVITY 
Reagents:
Phosphate buffer No.l: 10 mM K 2 HPO 4 , 3 0 mM KCl pH 7.4 
Ethanol solution: 10 % in the phosphate buffer No.l 
Triton X-100 solution: 10% in phosphate buffer No.l 
Phosphate buffer No.2: 5 mM KHgPO^, 5 mM K 2 HPO 4 , pH 7.0 
H 2 O 2 solution: 6 mM in phosphate buffer No.2 
H 2 SO4 solution: 6 N in water 
KMn0 4  solution: 0.01 N in water 
Instrument:
Branson Sonifier 450 
lEC B-20A Centrifuge 
Bausch & Lomb Spectronic 21 
Procedure;
1) . Tissue samples were sonicated for 1 minute at the
output setting at 5 in ice-cold phosphate buffer No.l. 
The homogenate was then centrifuged at 10,000 rpm for 
10 minutes in the refrigerated (1-3°C) centrifuge.
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2 ). 0 . 1  ml of the supernatant was transferred to another 
tube and 10 ul of ethanol solution was added. The 
mixture was kept on ice for 30 minutes.
3) . 10 ul of Triton X-100 solution was added into the
mixture.
4) . The mixture was diluted with 5 ml of phosphate buffer
No.l to prepare the final sample for assay.
5) . 5 ml of cold H 2 O 2 solution was added to each of two
reaction vials labelled sample and blank. The reaction 
was initiated by adding 0.5 ml of sample or blank (0.5 
ml of phosphate buffer No.l) to the vials.
6 ). After exactly 3 minutes, the reaction was stopped by
rapidly adding 1  ml of H 2 SO4 solution to each tube.
7). A spectrophotometric standard was preparedby adding 5.5 
ml of phosphate buffer No. 2, 1 ml of H 2 SO4 solution and 
7 ml of KMn 0 4  solution to the vial. The readout of the 
spectrophotometer was adjusted to read 1 . 0  absorbance 
unit for the standard.
8 ) . 7 ml of KMn0 4  reagent was added rapidly to each of the
remaining reaction mixtures from step (6 ) , mixed 
thoroughly, and read at 480 nm within 3 0-60 seconds.
9) . Since the decomposition of H 2 O 2 by catalase followed
first-order kinetics, the catalase activity was 
expressed by the first-order reaction rate constant, 
k=log(So/S3 )x2 .3 /t. Here, Sq = l-(the absorbance of 
blank), S 3 = l-(the absorbance of sample) and t = 3 min.
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